Literature DB >> 23175287

Performance characteristics of current-generation Immulite 2000 TORCH Assays.

A R Centonze1, E Tonolli, R Fontana.   

Abstract

The performances of seven Immulite 2000 (Siemens Healthcare Diagnostics) TORCH (Toxoplasma gondii, other microorganisms, rubella virus, cytomegalovirus, and herpes simplex virus) assays were evaluated in comparison with the performances of the ETI-MAX 3000 (DiaSorin) TORCH assays. The two systems demonstrated good agreement, and given their sensitivity, specificity, and positive predictive value, they can be used with confidence for TORCH prenatal screening.

Mesh：

Year:  2012        PMID： 23175287      PMCID： PMC3535776          DOI： 10.1128/CVI.00106-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  23 in total

1.  Antenatal screening for hepatitis B and antibodies to Toxoplasma gondii and rubella virus: evaluation of two commercial immunoassay systems.

Authors:  R J Diepersloot; H Dunnewold-Hoekstra; J Kruit-Den Hollander; F Vlaspolder
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

2.  Persistence of IgM antibodies to cytomegalovirus-induced late antigen in pregnancy and postpartum.

Authors:  L Gärtner; M Kunkel; H Oberender
Journal:  Acta Virol       Date:  1983-01       Impact factor: 1.162

3.  [Evaluation of the Immulite 2000 Toxoplasma quantitative IgG et Toxoplasma IgM for the diagnosis of human toxoplasmosis].

Authors:  A Dao; B Fortier
Journal:  Ann Biol Clin (Paris)       Date:  2001 Mar-Apr       Impact factor: 0.459

Review 4.  Toxoplasmosis, parvovirus, and cytomegalovirus in pregnancy.

Authors:  Deborah M Feldman; Diane Timms; Adam F Borgida
Journal:  Clin Lab Med       Date:  2010-06-15       Impact factor: 1.935

Review 5.  Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity.

Authors:  Maija Lappalainen; Klaus Hedman
Journal:  Ann Ist Super Sanita       Date:  2004       Impact factor: 1.663

6.  Serodiagnosis of toxoplasma infection using a purified parasite protein (P30).

Authors:  F Santoro; D Afchain; R Pierce; J Y Cesbron; G Ovlaque; A Capron
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

7.  Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies.

Authors:  L Gras; R E Gilbert; M Wallon; F Peyron; M Cortina-Borja
Journal:  Epidemiol Infect       Date:  2004-06       Impact factor: 2.451

8.  Screening for infectious diseases.

Authors:  Stefan Gerber; Patrick Hohlfeld
Journal:  Childs Nerv Syst       Date:  2003-06-14       Impact factor: 1.475

9.  Use of IgG Avidity test in case definitions of toxoplasmosis in pregnancy.

Authors:  C Zotti; L Charrier; M Giacomuzzi; A Moiraghi Ruggenini; M Mombrò; C Fabris; P Marocchetti; R Alfieri; R Leto; N Renzi; R Milano; M A Lievre; M Colozza; D Zanella; G Antona; M C Paschero; F Tosetti; D Miglietti; T Nicoletta; G De Renzi; F Tinivella; M Donati; A Ferrini; G Crotti; L Coucourde; G C Guazzotti; A Gera; A Malabaila; C Di Natale; M L Rabozzi; C Ginardi; T Bruzzone; C Canepa; M Fruttero; G Mastracchio; S Valle; M Toppino; N Forno; P Bellingeri; W Caraccio; C Lazzara; V Decaroli; E Pedrazzi; S Gomella
Journal:  New Microbiol       Date:  2004-01       Impact factor: 2.479

Review 10.  TORCH Infections. Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections.

Authors:  Barbara J Stegmann; J Christopher Carey
Journal:  Curr Womens Health Rep       Date:  2002-08
View more
  1 in total

Review 1.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.